Low expression of CDK5RAP3 and DDRGK1 indicates a poor prognosis in patients with gastric cancer

Figure 1 Expression levels of CDK5RAP3 and DDRGK1 in gastric cancer and adjacent non-tumor tissues. A: Immunohistochemical staining of CDK5RAP3 and DDRGK1 expression in gastric cancer tissue and the criteria for immunohistochemistry scores following the intensity of positive signals. Scale bar = 100 μm. B: Western blot of CDK5RAP3 and DDRGK1 in gastric cancer and adjacent non-tumor tissues in nine patients. C: Western blot of CDK5RAP3 and DDRGK1 in five gastric cancer cells. D: CDK5RAP3 and DDRGK1 expression scores are shown as box plots, with the horizontal lines representing the median; the bottom and top of the boxes representing the 25^th and 75^th percentiles, respectively, and the vertical bars representing the range of data. The expression of CDK5RAP3 and DDRGK1 in gastric tumor tissues and respective adjacent non-tumor tissues was compared using the t-test. n = 135 (P < 0.001).

Figure 2 Kaplan-Meier analysis of the correlation between the expression of CDK5RAP3 and DDRGK1 and the overall survival of gastric cancer patients.

Figure 3 Kaplan-Meier analysis of the correlation between the combined expression of CDK5RAP3 and DDRGK1 with the overall survival of gastric cancer patients.

Figure 4 Receiver operating characteristic analysis of the sensitivity and specificity of the predictive value of DDRGK1 expression model, CDK5RAP3 expression model, the combined CDK5RAP3 and DDRGK1 model and the TNM model. A: Co-expression of CDK5RAP3 and DDRGK1 were significantly correlated with TNM stage. B: The area under the ROC curve was 0.649 (0.548-0.751) for the co-expression of CDK5RAP3 and DDRGK1 model, 0.598 (0.486-0.693) for the CDK5RAP3 expression model, 0.605 (0.501-0.708) for the DDRGK1 expression model, and 0.659 (0.562-0.756) for the TNM model.